At a glance
ClinicalIndex Comparison RecordN/ACompleted· 52 enrolled
Drug / intervention
Ablathermydevice
Likely dose
Not stated in record
Key inclusion· 3
- ✓Colorectal cancer diagnosis
- ✓Hepatic metastases that are unresectable by classical surgery
- ✓Performance status less than 2
Key exclusion· 0
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy. A Phase 2 Study.
In Brief
A clinical study evaluating Ablathermy for Colorectal Cancer. Completed, enrolled 52 participants across 12 sites.
Detailed Summary
The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. Patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2003
First PostedSep 2005
Primary CompletionDec 2008
Study CompletionMay 2010
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartJun 1, 2003
Primary CompletionDec 1, 2008
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 20.8 years ago
Interventions
Ablathermydevice